ZyVersa Therapeutics, Inc. (ZVSA)
NASDAQ: ZVSA · IEX Real-Time Price · USD
0.563
-0.012 (-2.11%)
At close: Apr 23, 2024, 3:59 PM
0.577
+0.014 (2.51%)
After-hours: Apr 23, 2024, 7:59 PM EDT
Company Description
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases.
The company engages in the development of VAR 200, a cholesterol efflux mediator, which is in Phase 2a clinical trial to the treatment of multiple renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic nephropathy; and IC 100, a monoclonal antibody inflammasome ASC inhibitor that is in preclinical stage for treatment of multitude of inflammatory diseases.
ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
ZyVersa Therapeutics, Inc.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Stephen C. Glover |
Contact Details
Address: 217 W. Main Street Somerville, New Jersey 08876 United States | |
| Phone | 908-370-5102 |
| Website | zyversa.com |
Stock Details
| Ticker Symbol | ZVSA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001859007 |
| ISIN Number | US98987D2018 |
| Employer ID | 86-2685744 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Stephen C. Glover | Co-Founder, Chairman, Chief Executive Officer and President |
| Peter Wolfe | Chief Financial Officer and Secretary |
| Karen A. Cashmere | Chief Commercial Officer |
| Melda Uzbil O'connell | Senior Vice President of Corporate Development |
| Dr. Pablo A. Guzman FACC, M.D. | Chief Medical Officer, Senior Vice President of Medical Affairs and Chairman of Renal Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2024 | 8-K | Current Report |
| Mar 27, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 25, 2024 | 10-K | Annual Report |
| Mar 19, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 8, 2024 | 8-K | Current Report |
| Mar 8, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 1, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |